Search Results for 'catalent'
Contract Service Directory Companies
Featured Companies
View All Buyers Guide Companies »
-
Breaking News | cGMP Manufacture | Industry News
Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
Will add 107,000 sq.-ft. to the site’s manufacturing footprint expanding highly potent material handling capabilities and lab space.05.19.22
-
Breaking News | Drug Development
Catalent Introduces UpTempo Virtuoso Platform
Standardizes and streamlines many time-consuming steps in AAV manufacturing to significantly reduce gene therapy development time.05.16.22
-
Breaking News | Facilities | Industry News
Catalent Expands Nasal Drug Development and Manufacturing Capabilities
Marks the first phase of a multi-million-dollar investment at the site in Morrisville, NC.04.28.22
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Catalent Acquires Erytech's Commercial-Scale Cell Therapy Mfg. Facility
30,900-sq.-ft. facility in Princeton, NJ houses 16 suites for cGMP product production, and labs for analytical, quality control and microbiology testing.04.25.22
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Catalent Bolsters Biologics Capabilities
Invests $350 million in integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana, facility.04.21.22
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
Catalent Expands Biologics Capabilities in UK and Europe
Acquires facility in Oxfordshire and will invest up to $160 million to complete and equip it with state-of-the-art capabilities for biologics and vaccines.04.06.22
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development
Catalent Appoints Dr. Frederic Cedrone as VP, Corporate Innovation
Cedrone has more than 25 years of experience in biologic drug development, including cell and gene therapies.03.25.22
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Fill/Finish | Industry News
Catalent Completes $30M Project at Limoges Facility
Transforms the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services and packaging.03.16.22
-
Breaking News | Collaborations & Alliances | Formulation Development
TFF Pharma, Catalent Enter Dry Powder Development and Manufacturing Agreement
Will focus on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery.03.01.22
-
Breaking News | Clinical Trial Materials | Cold Chain Management | Facilities | Industry News
Catalent Expands Shanghai Facility
To increase capacity for temperature-controlled storage and distribution of clinical supplies, as well as additional secondary packaging capabilities.02.15.22
-
Breaking News | Industry News
Catalent Completes Expansion of Advanced Containment Capabilities
Expansion in large-scale isolator units at Malvern and Dartford, UK facilities to provide advanced containment capabilities for highly potent drug compounds.01.25.22
-
Breaking News | Drug Development | Industry News | Solid Dosage/Creams/Ointments
Catalent Launches New Xpress Pharmaceutics Service
Expedites development of oral drugs for adaptive phase 1 clinical trials.01.18.22
-
Breaking News | Cold Chain Management | Facilities | Industry News | Packaging & Tracking
Catalent Increases Specialized Packaging Capabilities
Expands Philadelphia facility to support growing biologic and cell and gene therapy markets.01.11.22
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer
BrainStorm, Catalent Complete Tech Transfer for NurOwn
Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.12.07.21
-
Breaking News | Clinical Trial Materials | Industry News
Catalent Opens New Clinical Supply Facility in San Diego
The 24,000-sq.-ft. facility was established to support integrated development, clinical packaging, and distribution solutions for Phase 1-3 clinical studies.10.28.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Catalent Invests $230M in Harmans Gene Therapy Campus
Will house 18 CGMP viral vector manufacturing suites designed to accommodate multiple bioreactors up to 2,000-liter scale and commercial manufacturing.10.26.21
-
Breaking News | Clinical Trial Materials | Industry News
Catalent Opens Clinical Supply Facility in Japan
The 6,000 square-meter site will provide flexible clinical supply services for both local and global pharma and biopharma companies.10.05.21
-
Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News | Solid Dosage/Creams/Ointments
Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals
Will make lead compound vonoprazan from Winchester, KY facility if approved by FDA.09.16.21
-
Breaking News | Promotions & Moves
Catalent Appoints GM of Philadelphia Clinical Supply Facility
Harold A. Jenkins III brings more than 28 years of leadership experience.08.13.21
-
Breaking News | Industry News
Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement
Novel formulation of glycopyrrolate will use Catalent’s Zydis ODT delivery technology for adjunctive therapy for the treatment of peptic ulcer.08.10.21
-
Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
VideoBites: Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics and more.Videos
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Catalent Completes RheinCell Therapeutics Acquisition
Plans to facilitate accelerated access to high-quality iPSC banks with integrated solutions from plasmid DNA manufacturing to clinical supply.08.04.21
-
Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News | Solid Dosage/Creams/Ointments
DisperSol, Catalent Enter Manufacturing Collaboration
To establish KinetiSol technology manufacturing hub for DisperSol’s pipeline.08.03.21
-
Breaking News | Formulation Development | Industry News
Catalent Launches New OptiDose Design Solution
Aims to help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.07.26.21
-
Bio News | Breaking News | Industry News
Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology
Designed to shorten drug substance development timelines by up to three months.07.22.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News
Catalent Plans $100M Expansion of Biologics Mfg. Capabilities in Italy
Initial phase includes installation of two 2,000-liter single-use bioreactors and associated investments to support early-and late-phase clinical development.07.21.21
-
Bio News | Breaking News | cGMP Manufacture | Clinical Trial Materials | Collaborations & Alliances | Industry News
Curtana and Catalent Enter Brain Cancer Drug Partnership
Sign development and manufacturing agreement for brain cancer drug CT-179.07.16.21
-
Breaking News | Formulation Development | Industry News
Catalent, JOS Pharmaceuticals Enter Zydis Formulation Agreement
Catalent to undertake a feasibility study for the potential development of a CBD product for use as an anesthetic leveraging its ODT technology.07.13.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News | Process Development
Catalent to Acquire RheinCell Therapeutics
Strengthens path towards industrialization of induced pluripotent stem cell-based therapies.06.25.21
-
Breaking News | Industry News | Vials
HERMA US Delivers Wrap-around Labelers to Catalent
Will support production of biologics, including COVID-19 vaccines.Kristin Brooks 05.18.21
-
Breaking News | Industry News
HBC, Catalent Enter Innovative Softgel Alliance
Partnership will leverage Catalent’s OptiGel DR technology to develop a delayed-release formulation of HBC’s OmeGo fish oil.Kristin Brooks 05.12.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Catalent Acquires Commercial-Scale Plasmid DNA Mfg. Facility
Promethera’s Hepatic Cell Therapy Support SA include's 32,400 sq.-ft. facility in Gosselies, Belgium.Kristin Brooks, Contract Pharma 05.06.21
-
Breaking News | Cold Chain Management | Collaborations & Alliances | Industry News | Packaging & Tracking
Catalent and Stirling Ultracold Enter Cold Chain Partnership
To establish energy-efficient cold chain capabilities for biologics and emerging modalities.Tim Wright, Editor, Contract Pharma 04.29.21
-
Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Development
AavantiBio, Catalent Enter Gene Therapy Alliance
Aims to advance AavantiBio’s gene therapy pipeline, including its lead program in Friedreich’s Ataxia (FA)Kristin Brooks 04.28.21
-
Breaking News | Clinical Trial Materials | Cold Chain Management | Facilities | Industry News | Lyophilization
Catalent Adds Cryogenic Capabilities at Philadelphia Facility
Bolsters clinical supply services at site to meet growing demand for cell and gene therapy development.Tim Wright, Editor, Contract Pharma 04.15.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
Catalent Biologics Completes Madison Expansion
More than doubles overall CGMP-scale capacity increasing the number of manufacturing suites at the site to five.Kristin Brooks 04.13.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Fill/Finish | Industry News
Moderna, Catalent Enter Long-Term Strategic Vax Pact
Catalent to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs.Kristin Brooks 04.06.21
-
Breaking News | Industry News
SK Capital Completes Acquisition of BFS from Catalent Pharma Solutions
Renames the business to Woodstock Sterile Solutions.Charles Sternberg, Assistant Editor 03.31.21
-
Breaking News | Formulation Development | Industry News
Cybin to Leverage Catalent’s Zydis for Psychiatric Drug
To apply Zydis orally disintegrating tablet (ODT) technology for delivery of Cybin’s potential therapy for treatment-resistant psychiatric disorders.Kristin Brooks 03.22.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Catalent Expands Partnership with J&J
To significantly increase capacity for sterile manufacturing and packaging of COVID-19 vaccine in Italy.Tim Wright, Editor, Contract Pharma 03.17.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Facilities | Industry News
Catalent Acquires Delphi Genetics
Launches US plasmid manufacturing site to establish global pDNA development and manufacturing capabilities.Tim Wright, Editor, Contract Pharma 02.23.21
-
Breaking News | cGMP Manufacture | Industry News
Catalent, Aurinia Ink LUPKYNIS Commercial Supply Pact
Catalent will manufacture LUPKYNIS as a softgel dosage form at its pharmaceutical softgel center of excellence in St. Petersburg, FL.Kristin Brooks 02.18.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News
Catalent, Trizell Enter Cell Therapy Deal
Sign development and manufacturing agreement with for macrophage-based advanced cell therapy.Tim Wright, Editor, Contract Pharma 02.08.21
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News
Catalent, Decibel Team Up for Hearing Loss Treatment
Enter development and manufacturing agreement for dual-vector gene therapy for the treatment of congenital hearing loss.Tim Wright, Editor, Contract Pharma 02.04.21
-
Breaking News | cGMP Manufacture | Collaborations & Alliances | Drug Delivery | Facilities | Industry News | Solid Dosage/Semi-solids
Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
The CDMO pays $80 million for dry powder inhaler spray drying, capsule manufacturing and packaging operations in Boston area.Contract Pharma Staff 01.13.21
-
Aseptic Processing | Breaking News | Collaborations & Alliances | Parenterals
Catalent Divests Blow-Fill-Seal Sterile CDMO Business
SK Capital makes the acquisition; new independent company to be formed.Contract Pharma Staff 01.07.21
-
Breaking News | cGMP Manufacture | Industry News
Passage Bio, Catalent Begin cGMP Mfg. for Gene Therapies
Completion of dedicated cGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS product candidates.Contract Pharma Staff 12.10.20
-
Breaking News | Drug Development | Promotions & Moves
Catalent Appoints Minakuchi Facility GM
Nakaya “Nick” Matsumaru joins the company from SymBio Pharmaceuticals.Contract Pharma Staff 12.10.20
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Catalent Invests $10M in Isolator Capabilities to Expand Micronization
Will allow flexible jet milling ops to be carried out at sites in Malvern, PA and Dartford, U.K. under high containment.Contract Pharma Staff 12.04.20
-
Breaking News | cGMP Manufacture | Industry News
Catalent, Blueprint Enter GAVRETO Commercial Supply Pact
Following FDA approval and tech transfer, the Catalent team in Kansas City will support commercial supply of the non-small cell lung cancer drug.Contract Pharma Staff 11.23.20
